Selecxine
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Selecxine - overview
Established
2018
Location
Pohang, Gyeongsangbuk, South Korea
Primary Industry
Biotechnology
About
Based in Pohang, South Korea, and founded in 2018, Selecxine operates as a biopharmaceutical development company that develops anti-cancer immunotherapeutics. In 2018, the company was awarded the Innovative Technology Support Award by the Ministry of SMEs and Startups. In 2019, the company developed TCB2 technology, an anti-human interleukin-2 antibody agent. In 2020, Selecxine was again selected as one of the most outstanding companies by the Ministry of SMEs and Startups.
In May 2020, Selecxine raised KRW 13. 7 billion in series A funding from new investors BM Ventures, Hanwha Investment & Securities, K-Run Ventures, Lighthouse Combined Investment, Medytox Venture Investment, POSCO Capital, Quantum Ventures Korea, SJ Investment Partners, and Stonebridge Ventures. In 2021, the company registered a TCB2 patent filing in the USA, Australia, and Russia. The current CEO of the company is Jun-Young Lee.
Selecxine develops antibody platform technology for anti-cancer immunotherapeutics. Its main platform technology is SLC-3010, which is an immune-mediated anti-cancer therapeutics for anti-human IL-2 antibody (TCB2).
Current Investors
IMM Investment, Posco Investment, SJ Investment Partners
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.selecxine.com
Verticals
HealthTech
Company Stage
Series B
Total Amount Raised
Subscriber access only
Selecxine - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.